Oncology Institute
TOIThe Oncology Institute, Inc. (NASDAQ: TOI) is a publicly traded, value-based community oncology practice operating in the United States. Its primary business focus is the delivery of integrated cancer care, including medical oncology, hematology, radiation oncology, and ancillary therapies, directly within community settings. The company’s model is structured around value-based care arrangements, which tie reimbursement to patient outcomes and cost efficiency rather than the volume of services provided. This approach aims to manage the total cost of care while maintaining accessibility for patients outside of major hospital systems. A key component of The Oncology Institute’s service offering is its clinical research program. The company maintains a dedicated research division that facilitates patient participation in oncology clinical trials at the community level. This provides patients with potential access to novel and investigational cancer therapies within their local care environment. The company’s operations are concentrated exclusively within the therapeutic area of oncology, encompassing a broad range of cancer types as treated in a general community oncology practice. As a public company, The Oncology Institute’s performance and strategy are detailed in its filings with the U.S. Securities and Exchange Commission. Its community-based, value-oriented model represents a specific approach within the broader oncology services and biotech sectors, focusing on the management and treatment of cancer through coordinated care networks.
TOI · Stock Price
Historical price data
About
The Oncology Institute, Inc. (NASDAQ: TOI) is a publicly traded, value-based community oncology practice operating in the United States. Its primary business focus is the delivery of integrated cancer care, including medical oncology, hematology, radiation oncology, and ancillary therapies, directly within community settings. The company’s model is structured around value-based care arrangements, which tie reimbursement to patient outcomes and cost efficiency rather than the volume of services provided. This approach aims to manage the total cost of care while maintaining accessibility for patients outside of major hospital systems. A key component of The Oncology Institute’s service offering is its clinical research program. The company maintains a dedicated research division that facilitates patient participation in oncology clinical trials at the community level. This provides patients with potential access to novel and investigational cancer therapies within their local care environment. The company’s operations are concentrated exclusively within the therapeutic area of oncology, encompassing a broad range of cancer types as treated in a general community oncology practice. As a public company, The Oncology Institute’s performance and strategy are detailed in its filings with the U.S. Securities and Exchange Commission. Its community-based, value-oriented model represents a specific approach within the broader oncology services and biotech sectors, focusing on the management and treatment of cancer through coordinated care networks.